Eurofins Discovery, a provider of services and products to the drug discovery industry, has formed a collaboration with Escient Pharmaceuticals. Eurofins Discovery’s integrated services are marketed under the brand name of DiscoveryOne.
 
Escient recently launched in San Diego with $40 million in Series A financing and is leveraging Eurofins’ expertise in assay development and GPCR drug discovery to identify novel therapeutics targeting Mas-Related G-Protein Receptors (Mrgpr). Under the terms of the ongoing collaboration, Eurofins will support in vitro preclinical discovery efforts for Escient’s programs by providing expertise and services. 
 
“The preclinical discovery support required for Escient’s novel drug targets plays well to Eurofins’ expertise and capabilities and this collaboration will greatly expedite our discovery path,” said Marcus Boehm, chief scientific officer, Escient.
 
Christina Shasserre, senior vice president, Eurofins Discovery, said, “We are thrilled with the value that we can offer our clients. We have been offering services for all phases of drug discovery and can now assemble this offering into an integrated service with program management staffed from experts in drug discovery, termed DiscoveryOne. This will provide our clients with the critical expertise to support their delivery of a preclinical candidate.”